06 November 2018

Unaudited Results for the nine months to 30 September 2018

American Society of Anesthesiology (ASA) San Francisco, CA

 October 13-17

15 October 2018

Further update on FDA regulatory review of BARHEMSYS™ 

08 October 2018

Update on FDA regulatory review of BARHEMSYS™

Health Connect Partners (HCP), Los Angeles, CA

October 1-3

Future Pharma, Boston, MA

September 26-28

Integrated Delivery Network Summit and Reverse Expo (IDN), Phoenix, AZ

September 17-19

14 September 2018

Positive BARHEMSYS™ Phase 3 Treatment Data Published in Anesthesia & Analgesia

07 September 2018

Interim Results for the First Half Year 2018

SG2 Executive Summit, Chicago, IL

July 23-25

09 July 2018

Operating Update for the First Half 2018

02 July 2018

$30 Million Credit Facility with Hercules Technology Growth Capital Secured to Support Intended Commercialisation of BARHEMSYS™ in the US

LSX CEO Forum, London, England

June 27

American Society of Metabolic and Bariatric Surgery (ASMBS), New York City

June 14-16

Jefferies 2018 Healthcare Conference, New York City

June 5-8

2018 BIO international Convention, Boston, MA

June 4-7

American Society of Health-System Pharmacists (ASHP), Denver, CO

June 2-6

Bio€quity Europe, Ghent, Belgium

May 14-16

Society for Ambulatory Anesthesia (SAMBA), Miami, FL

May 3-5

American College of Obstetricins & Gynaecology (ACOG), Austin, TX

April 27-30

2018 World Congress on Regional Anesthesia & Pain Medicine (ASRA), New York City

April 19 - 21

11 April 2018

US Commercial Operations for BARHEMSYS™ (formerly BAREMSIS®) Expanded Four Key Appointments

15 March 2018

BARHEMSYS™ (formerly BAREMSIS®) Prevents Post-Operative Nausea & Vomiting In High-Risk Patients (published in Anesthesiology)

02 March 2018

Acacia Pharma - Prospectus

02 March 2018

Acacia Pharma Successfully Prices Its Initial Global Offering At Eur 3.60 Per Share Raising Eur 40 Million